Bml Capital Management, LLC Athira Pharma, Inc. Transaction History

Bml Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$2.24 - $4.15 $1.24 Million - $2.3 Million	-554,362 Reduced 38.12%	900,000 $2.47 Billion
Q4 2023 Jan 30, 2024	SELL	$1.39 - $2.46 $347,500 - $615,000	-250,000 Reduced 14.67%	1,454,362 $3.53 Billion
Q3 2023 Oct 23, 2023	SELL	$1.9 - $3.16 $305,035 - $507,322	-160,545 Reduced 8.61%	1,704,362 $3.44 Billion
Q1 2023 Apr 14, 2023	BUY	$2.26 - $4.22 $2.6 Million - $4.85 Million	1,150,144 Added 160.91%	1,864,907 $4.66 Billion
Q4 2022 Feb 13, 2023	BUY	$2.76 - $3.71 $1.97 Million - $2.65 Million	714,763 New	714,763 $2.27 Billion

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Bml Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bml Capital Management, LLC with notifications on news.